Robertson Stephens Wealth Management LLC Acquires Shares of 17,928 Moderna, Inc. $MRNA

Robertson Stephens Wealth Management LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 17,928 shares of the company’s stock, valued at approximately $529,000.

A number of other large investors have also recently made changes to their positions in MRNA. AQR Capital Management LLC bought a new position in shares of Moderna in the first quarter valued at $415,000. NewEdge Advisors LLC lifted its stake in shares of Moderna by 732.7% in the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after buying an additional 10,185 shares in the last quarter. United Services Automobile Association bought a new position in shares of Moderna in the first quarter valued at $230,000. Focus Partners Wealth lifted its stake in shares of Moderna by 58.7% in the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock valued at $668,000 after buying an additional 8,706 shares in the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Moderna by 5.2% in the second quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock valued at $1,348,000 after buying an additional 2,410 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on MRNA shares. TD Cowen reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Citigroup reissued a “neutral” rating on shares of Moderna in a research report on Monday, February 16th. Barclays raised their price target on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a research report on Thursday, April 2nd. Jefferies Financial Group set a $37.00 price target on shares of Moderna and gave the company a “hold” rating in a research report on Tuesday, March 3rd. Finally, Morgan Stanley set a $33.00 price target on shares of Moderna in a research report on Friday. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $35.73.

Moderna Stock Performance

NASDAQ MRNA opened at $47.30 on Tuesday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $59.55. The company has a 50-day simple moving average of $51.84 and a 200 day simple moving average of $39.47. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. The company has a market capitalization of $18.68 billion, a PE ratio of -5.80 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company had revenue of $389.00 million for the quarter, compared to analysts’ expectations of $236.37 million. During the same quarter last year, the business posted ($2.52) EPS. The business’s quarterly revenue was up 260.2% on a year-over-year basis. On average, research analysts predict that Moderna, Inc. will post -8 EPS for the current year.

Insider Transactions at Moderna

In related news, Director Abbas Hussain sold 5,682 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the sale, the director owned 12,066 shares in the company, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 160,009 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the sale, the president owned 1,457,427 shares of the company’s stock, valued at $71,180,734.68. This trade represents a 9.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.